Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis

OBJECTIVE: Biologic drug therapies represent a huge advance in the treatment of rheumatoid arthritis (RA). However, very good disease control is achieved in only 30% of patients, making identification of biomarkers of response a research priority. We undertook this study to test our hypothesis that...

Descripción completa

Detalles Bibliográficos
Autores principales: Plant, Darren, Webster, Amy, Nair, Nisha, Oliver, James, Smith, Samantha L., Eyre, Steven, Hyrich, Kimme L., Wilson, Anthony G., Morgan, Ann W., Isaacs, John D., Worthington, Jane, Barton, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914881/
https://www.ncbi.nlm.nih.gov/pubmed/26814849
http://dx.doi.org/10.1002/art.39590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914881/
https://www.ncbi.nlm.nih.gov/pubmed/26814849
http://dx.doi.org/10.1002/art.39590

Ejemplares similares